home / stock / grcl / grcl news


GRCL News and Press, Gracell Biotechnologies Inc. From 07/26/21

Stock Information

Company Name: Gracell Biotechnologies Inc.
Stock Symbol: GRCL
Market: NASDAQ
Website: gracellbio.com

Menu

GRCL GRCL Quote GRCL Short GRCL News GRCL Articles GRCL Message Board
Get GRCL Alerts

News, Short Squeeze, Breakout and More Instantly...

GRCL - Gracell Biotechnologies to Participate in Fireside Chat at the BTIG Virtual Biotechnology Conference

SUZHOU, China and PALO ALTO, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the tr...

GRCL - Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2021 Update

Halvorsen's 13F portfolio value decreased from $36.37B to $33.58B. The number of positions decreased from 96 to 94. Viking Global added Bank of America while reducing JPMorgan Chase and dropping Walt Disney. The top three positions are Microsoft, BridgeBio Pharma, and Fidelity Nat...

GRCL - Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021

SUZHOU, China and PALO ALTO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the tr...

GRCL - ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

GRCL - Gracell Biotechnologies Hosting Key Opinion Leader Webinar on High Risk Multiple Myeloma, Treatment Challenges and Dual-Targeting CAR-T with Overnight Manufacturing - a Novel Approach for Treatment of Multiple Myeloma

Gracell Biotechnologies Hosting Key Opinion Leader Webinar on High Risk Multiple Myeloma, Treatment Challenges and Dual-Targeting CAR-T with Overnight Manufacturing - a Novel Approach for Treatment of Multiple Myeloma Webinar on June 11 2021 at 8:00am EDT PR Newswire ...

GRCL - Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in June

SUZHOU, China and PALO ALTO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the tre...

GRCL - YALA, OBLN, ONTX and CRDF among midday movers

Gainers: Annovis Bio (ANVS) +250%.Jiuzi Holdings (JZXN) +27%.Longeveron (LGVN) +25%.Wah Fu Education (WAFU) +22%.Mesa Royalty Trust (MTR) +20%.Gracell Biotechnologies (GRCL) +20%.Obalon Therapeutics (OBLN) +16%.Yalla Group (YALA) +16%.VOC Energy Trust (VOC) +12%.Cyclo Therapeut...

GRCL - Annovis Bio, Gracell Biotechnologies leads healthcare gainers; Precipio, Cullinan Oncology among major losers

Gainers: Annovis Bio ANVS +112%, Gracell Biotechnologies (GRCL) +24%, Metacrine MTCR +16%, Sensei Biotherapeutics (SNSE) +14%, Longeveron (LGVN) +12%.Losers: Precipio (PRPO) -12%, Cullinan Oncology CGEM -8%, Navidea Biopharmaceutical...

GRCL - Gracell Biotechnologies to Host Clinical Update Conference Call and Webcast on June 4, 2021 at 11:00am EDT

SUZHOU, China and PALO ALTO, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the tre...

GRCL - Gracell Biotechnologies to Present Updated Results of GC012F FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma at ASCO 2021 and EHA 2021

Gracell Biotechnologies to Present Updated Results of GC012F FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma at ASCO 2021 and EHA 2021 PR Newswire SUZHOU, China and PALO ALTO, Calif. , May 19, 2021 ...

Previous 10 Next 10